Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Longitudinal [18F]GTP1 PET Imaging in Alzheimer's Disease
NCT02640092Phase 1Completed
- Sponsor
- Genentech
- Start
- Dec 2015
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of [18F]GTP1 in Alzheimer's disease (AD), sponsored by Genentech. Primary endpoint: Change in Standardized Uptake Value Ratio (SUVR) as Measured by [18F]GTP1 at 18 months. Started Dec 2015; status: completed.
02
Drugs
[18F]GTP1
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02640092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02640092.